Skip to content
OpenCapital
Get started

Johnson & Johnson JNJ ADVANCED — Sales to customers (Note 9)

Other product segments

ELECTROPHYSIOLOGY
$5.63B+7.0%
DARZALEX
$3.96B+22.5%
Other
$2.9B+2.1%
SPINE,SPORTS & OTHER
$2.85B-2.5%
Tremfya
$1.61B+68.2%
GENERAL
$1.39B+4.9%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
$1.04B+15.0%
CONTACT LENSES / OTHER
$969M+5.4%
ERLEADA
$949M+23.1%
TRAUMA
$833M+7.9%
SPINE & OTHER
$694M+3.4%
IMBRUVICA
$660M-6.9%
STELARA
$656M-59.6%
SIMPONI / SIMPONI ARIA
$647M-1.8%
XARELTO
$642M-7.0%
OPSUMIT/OPSYNVI
$606M+16.1%
CARVYKTI
$597M+61.8%
UPTRAVI
$483M+7.1%
SPRAVATO
$468M+46.3%
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA
$443M+9.9%
HIPS
$436M+6.6%
Remicade
$422M-9.6%
KNEES
$420M+8.0%
EDURANT/rilpivirine
$409M+14.2%
other cardiovascular
$397M+4.5%
SURGICAL
$396M+9.7%
CAPLYTA
$270M—
OTHER NEUROSCIENCE
$262M-5.4%
RYBREVANT + LAZCLUZE
$257M+82.3%
Tecvayli
$202M+33.8%
Other Oncology
$192M-10.3%
TALVEY
$152M+76.7%
CONCERTA/Methylphenidate
$136M-8.1%
OTHER IMMUNOLOGY
$46M+4,500%
OTHER INFECTIOUS DISEASES
$37M-9.8%

Similar metrics at other companies

Novanta logo
NOVTAdvanced Surgery — Revenue
$62.53M+11.3%
Kulicke & Soffa Industries logo
KLICAdvanced Solutions — Total Revenue
$24.48M+38.8%
nLIGHT, Inc. logo
LASRAdvanced Development — Total Revenue
$21.98M+37.5%
Ingram Micro logo
INGMAdvanced Solutions — Net Sales
$4.4B+4.4%
Vicor logo
VICRAdvancedproducts — Revenue
$64.92M+8.5%
Baxter International logo
BAXAdvanced Surgery — Net Sales
$304M+13.4%

Other financials

Income statement

See full
Revenue$24.1B+9.9%
Gross profit$16.0B+9.8%
Operating income$6.3B+2.3%
Net income$5.2B-52.4%
EPS (diluted)$2.14-52.9%

Balance sheet

See full
Cash & equivalents$21.7B-43.6%
Total debt$55.0B+5.2%
Total equity$81.2B+3.9%
Total assets$200.89B+3.7%

Cash flow

See full
Operating cash flow$2.5B-39.8%
CapEx$1.0B+31.9%
Free cash flow$1.5B-56.6%

Valuation

See full
Market cap$623.71B+66.9%
Enterprise value$657.01B+61.9%
P/E29.6×+13.2×
P/S6.5×+2.3×

Profitability

See full
Gross margin67.8%-0.5pp
Operating margin26.4%+2.8pp
Net margin21.8%-2.6pp
FCF margin18.5%-4.3pp

Returns & leverage

See full
Return on equity26.4%-3.0pp
Debt / equity0.7×0.0×
Current ratio1×-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's advanced — sales to customers (note 9).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Johnson & Johnson's ADVANCED — sales to customers (note 9)?
Johnson & Johnson (JNJ) reported ADVANCED — sales to customers (note 9) of $1.12B in Q1 2026.
How has Johnson & Johnson's ADVANCED — sales to customers (note 9) changed year-over-year?
Johnson & Johnson's ADVANCED — sales to customers (note 9) increased by 4.7% year-over-year, from $1.07B to $1.12B.
What is the long-term trend for Johnson & Johnson's ADVANCED — sales to customers (note 9)?
Over 4 years (2021 to 2025), Johnson & Johnson's ADVANCED — sales to customers (note 9) has grown at a -0.2% compound annual growth rate (CAGR), from $4.62B to $4.58B.
What does ADVANCED — sales to customers (note 9) mean?
This metric represents the total revenue generated from the Advanced product segment, reflecting the market demand for the company's specialized medical technology or advanced therapeutic solutions. It serves as a key indicator of the segment's contribution to the overall corporate top-line performance and its ability to capture market share in high-value healthcare niches. By isolating this segment, investors can assess the growth trajectory and commercial success of the company's most sophisticated product offerings.